Bayer reports rivaroxaban data

Bayer AG (Xetra:BAY) said oral rivaroxaban was non-inferior to current standard therapy on the primary endpoint of the cumulative incidence of symptomatic recurrent venous thromboembolism (VTE) in the Phase III EINSTEIN-DVT trial to treat acute symptomatic deep vein thrombosis (DVT) without symptoms of pulmonary embolism (PE). Current standard therapy consists of initial Lovenox enoxaparin from sanofi-aventis Group (Euronext:SAN; NYSE:SNY), followed by a vitamin K antagonist. The open-label, international trial enrolled more than 3,400 patients. Data will be presented at the European Society of Cardiology meeting in Stockholm this month. ...